Gene · 3623
Papers1,777
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,777
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular insights of drug-resistant tuberculosis: genetic mutations and their profile. | Front Microbiol | 2025 | 41113631 | PubTator, text mining | PubMed |
| Innowave MTB/RIF/INH facilitates timely and accurate diagnosis of multiple-drug resistant tuberculosis as a near POCT technique: a multicenter prospective on-site performance evaluation study. | Ann Clin Microbiol Antimicrob | 2025 | 41013621 | PubTator, text mining | PubMed |
| Genotypic study of isolated resistance to isoniazid in the Mycobacterium tuberculosis complex in a Moroccan hospital. | Access Microbiol | 2025 | 40988883 | PubTator, text mining | PubMed |
| The gradual expansion of multiple intramedullary metastatic renal cell carcinoma in a patient with von Hippel-Lindau disease with multiple intramedullary hemangioblastomas: illustrative case. | J Neurosurg Case Lessons | 2025 | 40953499 | PubTator, text mining | PubMed |
| Advancements in the design and development of pyrazoline-based antimycobacterial agents: an update and future perspectives. | RSC Adv | 2025 | 40901459 | PubTator, text mining | PubMed |
| Investigating the Mechanism of Antimycobacterial and Antiproliferative Activity of (E)-N'-Benzylidenepyrazine-2-Carbohydrazides and their Derivatives. | ChemMedChem | 2025 | 40879650 | PubTator, text mining | PubMed |
| A scoping review about smoking, smoking cessation and their effects on anti-tuberculosis agents: insights into drug metabolisms, safety, and effectiveness. | Front Pharmacol | 2025 | 40741006 | PubTator, text mining | PubMed |
| A Novel Hypoxia-Immune Signature for Gastric Cancer Prognosis and Immunotherapy: Insights from Bulk and Single-Cell RNA-Seq. | Curr Issues Mol Biol | 2025 | 40729021 | PubTator, text mining | PubMed |
| Structure-based design, synthesis, computational screening and biological evaluation of novel pyrrole fused pyrimidine derivatives targeting InhA enzyme. | RSC Adv | 2025 | 40697459 | PubTator, text mining | PubMed |
| Designing Novel InhA Inhibitors for Antituberculosis Agents Using ab Initio Fragment Molecular Orbital Calculations. | ACS Omega | 2025 | 40687024 | PubTator, text mining | PubMed |
| Epidemiology and molecular characterization of multidrug-resistant Mycobacterium tuberculosis among patients with pulmonary symptoms in Kaduna State, Nigeria. | Acta Trop | 2025 | 40683583 | PubTator, text mining | PubMed |
| Bimodal Genomic Approach Predicting Semaphorin 7A (SEMA7A) as Prognostic Biomarker in Adrenocortical Carcinoma. | Cancers (Basel) | 2025 | 40647379 | PubTator, text mining | PubMed |
| Prevalence and molecular characterization of drug-resistant Mycobacterium tuberculosis in Heyuan City in China. | Front Cell Infect Microbiol | 2025 | 40575484 | PubTator, text mining | PubMed |
| Cuproptosis and cuproptosis-related cell death and genes: mechanistic links to spermatogenic cell death. | Cell Death Discov | 2025 | 40494847 | PubTator, text mining | PubMed |
| High-dose isoniazid for TB with low-to-moderate isoniazid resistance after 1 week of treatment. | JAC Antimicrob Resist | 2025 | 40406736 | PubTator, text mining | PubMed |
Design, synthesis and in silico molecular modelling studies of 2-Hydrazineyl-2-oxoethyl-4-(1H-pyrrol-1-yb) benzoate derivatives: a potent dual DHFR and ENR-reductase inhibitors with antitubercular, antibacterial and cytotoxic potential. | PLoS One | 2025 | 40388480 | PubTator, text mining | PubMed |
Evaluation of the therapeutic potential of a Schiff Base Compound: Pharmacokinetic profiling, molecular docking for Enoyl-Acyl carrier protein reductase (InhA), antimicrobial, and anticancer properties. | Int J Biol Macromol | 2025 | 40316109 | PubTator, text mining | PubMed |
| Regulating human oocyte maturation in vitro: a hypothesis based on oocytes retrieved from small antral follicles during ovarian tissue cryopreservation. | J Assist Reprod Genet | 2025 | 40261459 | PubTator, text mining | PubMed |
| Is Mycobacterial InhA a Suitable Target for Rational Drug Design? | ChemMedChem | 2025 | 40192582 | PubTator, text mining | PubMed |
| Expression and distribution of activin-follistatin-inhibin axis in the urinary bladder. | Front Mol Biosci | 2025 | 40144023 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3623/papers?page=3